Role of drug metabolism in drug discovery and development
Authors:
- 1 September 2001
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 21 (5) , 397-411
Abstract
Metabolism by the host organism is one of the most important determinants of the pharmacokinetic profile of a drug. High metabolic lability usually leads to poor bioavailability and high clearance. Formation of active or toxic metabolites will have an impact on the pharmacological and toxicological outcomes. There is also potential for drug–drug interactions with coadministered drugs due to inhibition and/or induction of drug metabolism pathways. Hence, optimization of the metabolic liability and drug–drug interaction potential of the new chemical entities are some of the most important steps during the drug discovery process. The rate and site(s) of metabolism of new chemical entities by drug metabolizing enzymes are amenable to modulation by appropriate structural changes. Similarly, the potential for drug–drug interactions can also be minimized by appropriate structural modifications to the drug candidate. However, the optimization of the metabolic stability and drug–drug interaction potential during drug discovery stage has been largely by empirical methods and by trial and error. Recently, a lot of effort has been applied to develop predictive methods to aid the optimization process during drug discovery and development. This article reviews the role of drug metabolism in drug discovery and development. © 2001 John Wiley & Sons, Inc. Med Res Rev, 21, No. 5, 397–411, 2001Keywords
This publication has 29 references indexed in Scilit:
- FDA Evaluations Using In Vitro Metabolism to Predict and Interpret In Vivo Metabolic Drug‐Drug Interactions: Impact on LabelingThe Journal of Clinical Pharmacology, 1999
- Knowledge-Based Expert Systems for Toxicity and Metabolism Prediction: DEREK, StAR and METEORSAR and QSAR in Environmental Research, 1999
- Oxidation of Acetaminophen to Its Toxic Quinone Imine and Nontoxic Catechol Metabolites by Baculovirus-Expressed and Purified Human Cytochromes P450 2E1 and 2A6Chemical Research in Toxicology, 1998
- Inhibition and Induction of Cytochrome P450 and the Clinical ImplicationsClinical Pharmacokinetics, 1998
- RitonavirClinical Pharmacokinetics, 1998
- Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic InteractionsClinical Pharmacokinetics, 1997
- Relevance of induction of human drug‐metabolizing enzymes: pharmacological and toxicological implicationsBritish Journal of Clinical Pharmacology, 1996
- The P450 Superfamily: Update on New Sequences, Gene Mapping, Accession Numbers, Early Trivial Names of Enzymes, and NomenclatureDNA and Cell Biology, 1993
- Quantitative relationships between structure and microsomal oxidation rate of 1,4-dihydropyridinesChemico-Biological Interactions, 1986
- Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics; a new class of agentsXenobiotica, 1982